Information Provided By: 
Fly News Breaks for February 20, 2020
LDOS
Feb 20, 2020 | 07:23 EDT
Stifel analyst Joseph DeNardi raised the firm's price target on Leidos to $130 from $90 after the company reported "strong" Q4 results, including cash flow that was well ahead of the company's prior guidance. Its guidance implies high-single digit organic growth when factoring in the Q3 commercial health divestitures, which will likely put Leidos at the high-end of the industry for organic growth in 2020, said DeNardi. However, he keeps a Hold rating on the shares given the stock's "upper-tier" valuation.
News For LDOS From the Last 2 Days
There are no results for your query LDOS
